UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

The New England journal of medicine, 2017-10, Vol.377 (17), p.1613-1629

2017

Volltextzugriff (PDF)

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 2020-12, Vol.146 (6), p.1397-1405

2020

Volltextzugriff (PDF)

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

The lancet respiratory medicine, 2017-05, Vol.5 (5), p.390-400

2017

Volltextzugriff (PDF)

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

The European respiratory journal, 2022-01, Vol.59 (1), p.2100396

2022

Volltextzugriff (PDF)

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

Clinical therapeutics, 2019-10, Vol.41 (10), p.2041-2056.e5

2019

Volltextzugriff (PDF)

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

Respiratory medicine, 2019-11, Vol.159 (C), p.105806-105806, Article 105806

2019

Volltextzugriff (PDF)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis

Respiratory research, 2019-05, Vol.20 (1), p.83-83, Article 83

2019

Volltextzugriff (PDF)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

Respiratory research, 2021-06, Vol.22 (1), p.171-171, Article 171

2021

Volltextzugriff (PDF)

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

Respiratory research, 2021-06, Vol.22 (1), p.1-184, Article 184

2021

Volltextzugriff (PDF)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

Respiratory research, 2019-07, Vol.20 (1), p.169-169, Article 169

2019

Volltextzugriff (PDF)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Allergy, asthma, and clinical immunology, 2019-09, Vol.15 (1), p.53-53, Article 53

2019

Volltextzugriff (PDF)

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Journal of allergy and clinical immunology, 2019-05, Vol.143 (5), p.1742-1751.e7

2019

Volltextzugriff (PDF)

Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2018-05, Vol.6 (3), p.874-882.e4

2018

Volltextzugriff (PDF)

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

Journal of allergy and clinical immunology, 2019-11, Vol.144 (5), p.1336-1342.e7

2019

Volltextzugriff (PDF)

Mepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB380-AB380

2017

Volltextzugriff (PDF)

Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB380-AB380

2017

Volltextzugriff (PDF)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Pediatric pulmonology, 2019-12, Vol.54 (12), p.1957-1967

2019

Volltextzugriff (PDF)

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis

Journal of allergy and clinical immunology, 2019-06, Vol.143 (6), p.2170-2177

2019

Volltextzugriff (PDF)

Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy

Journal of allergy and clinical immunology, 2020-06, Vol.145 (6), p.1713-1715

2020

Volltextzugriff (PDF)

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

The Journal of asthma, 2018-02, Vol.55 (2), p.152-160

2018

Volltextzugriff (PDF)

Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150–300 cells/μL

Respiratory medicine, 2019-05, Vol.151, p.139-141

2019

Volltextzugriff (PDF)

Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison

Respiratory medicine, 2017-02, Vol.123, p.140-148

2017

Volltextzugriff (PDF)

Multinational cohort study of mortality in patients with asthma and severe asthma

Respiratory medicine, 2020-04, Vol.165, p.105919-105919, Article 105919

2020

Volltextzugriff (PDF)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1755-1770

2021

Volltextzugriff (PDF)

Efficacy Of 100 Mg SC Mepolizumab For Severe Eosinophilic Asthma (SEA) Across Blood Eosinophil Counts: Meta-Analysis

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB101-AB101

2019

Volltextzugriff (PDF)

1 – 25 von 839

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(725)
Mit Volltextzugriff
(703)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(837)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(530)
Life Sciences & Biomedicine
(404)
Humans
(293)
Female
(166)
Male
(166)
Animals
(110)
Biological And Medical Sciences
(102)
Middle Aged
(101)
Adult
(87)
Medical Sciences
(74)
Technology
(73)
Aged
(69)
Mice
(58)
Physical Sciences
(57)
Neurosciences & Neurology
(55)
Surgery
(41)
Neurosciences
(39)
Fundamental And Applied Biological Sciences. Psychology
(38)
Social Sciences
(37)
Computer Science
(36)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB-FREE-00999 freely available EZB journals
(372)
MEDLINE
(370)
Ingenta Connect
(319)
Ovid SocietyJournals and Single Titles
(295)
NUS Single-Journal Subscriptions
(234)
Elsevier ScienceDirect Journals Complete
(140)
IngentaConnect Journals
(138)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(101)
Wiley-Blackwell Journals
(99)
JSTOR
(72)
Wiley Online Library
(64)
SpringerLink_现刊
(49)
Nature_系列刊
(39)
eBooks on EBSCOhost
(36)
Ebook Central Perpetual and DDA
(35)
Oxford Journals
(33)
Taylor & Francis Journals Complete
(24)
Nexis Uni
(24)
IEEE Xplore
(24)
SAGE Complete
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

Mepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial

Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis

Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150–300 cells/μL

Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison

Multinational cohort study of mortality in patients with asthma and severe asthma

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO

Efficacy Of 100 Mg SC Mepolizumab For Severe Eosinophilic Asthma (SEA) Across Blood Eosinophil Counts: Meta-Analysis

Suchergebnisse filtern